Peyronie’s Disease

Peyronie’s Disease, affecting 65,000 to 120,000 men each year, may be better managed by Enzyme Treatment when compared to traditional treatment, according to study results presented at the 2013 Annual A.U.A meeting. The results of the study holds promise for so many men affected by Peyronie’s Disease.

Peyronie’s Disease Symptoms

Commonly affecting men between the ages of 45 and 60, Peyronie’s Disease is signified by the development of fibrous scar tissue inside the penis resulting in curved and occasionally painful erections, as well as, varying degrees of sexual dysfunction, emotional distress and depression. Though the cause of Peyronie’s Disease is not fully understood, factors that may contribute to the disease include:  injury to the penis, inherited traits, and immune system disorders.

Peyronie’s Disease Treatment

Traditionally, surgery is the method of treatment. Soon, Enzyme Treatment may replace surgery to offer far less invasive option for men with Peyronie’s Disease that qualify. As Tobias Kohler, MD, Assistant Professor of Surgery, Division of Urology, SIU School of Medicine explains,  “This study suggests CCH treatment (Enzyme treatment) can have both physical and psychological improvements on those suffering with Peyronie’s disease,” said “The potential for offering patients an effective in-office medical treatment that does not involve surgery would truly advance the standard of care we as physicians are able to provide.”

Enzyme Treatment with injections of collagenase clostridium histolyticum (CCH), an enzyme that breaks down fibrous scar tissue, offers improvement in both penile curvature deformity and Peyronie’s disease symptoms, according to data from the Investigation for Maximal Peyronie’s Reduction Efficacy and Safety Studies (IMPRESS) I and II phase three trials presented at the 2013 Annual A.U.A Scientific Meeting. Results from a post-hoc meta-analysis showed CCH-treated study participant had a mean 34 percent improvement in penile curvature deformity compared with a mean 18.2 percent improvement in placebo-treated study participants. The mean change in Peyronie’s disease symptoms score also significantly improved in participants treated with CCH.

It is important to recognize that all information contained on this website cannot be considered to be specific medical diagnosis, medical treatment, or medical advice. As always, you should consult with a physician regarding any medical condition.